A new clinical trial shows adding a targeted breast cancer drug to hormonal therapy reduced the risk of cancer returning by 25% for women with early-stage disease.
TUESDAY, June 6, 2023 -- Here's some good news for women with the most common type of breast cancer: Adding a targeted breast cancer drug to hormonal therapy reduced the risk of cancer returning by 25% for women with early-stage disease, a new clinical trial shows.
“The findings show this combination is a treatment of choice for patients with stage 2 or stage 3 HR positive/HER2 negative breast cancer,” he added in a university news release. Ribociclib is already FDA-approved to treat metastatic breast cancer, meaning cancer that's advanced. It is one of three cyclin-dependent kinase inhibitors approved for combination treatment with standard hormone therapies.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Drug-dealing 82-year-old man gets unusual warning after 25 arrestsAn elderly German man was given his last chance to get right with the law after 24 previous drug dealing convictions, receiving his 'last warning' to avoid jail time.
Read more »
Deadly targeted shootings in San Antonio may be linked, Chief McManus saysSan Antonio Police Department Chief William McManus said officers are investigating a possible link between two targeted shootings that happened across the city over the weekend.
Read more »
How Fat Burden May Affect IBD Drug DosingTarget levels of infliximab in patients with IBD and high visceral adipose fat burden may be higher, suggesting the potential need to personalize dosing strategies.
Read more »
If You Wanna Travel Like A Pro, Flight Attendants Adore These 25 ThingsIf anyone knows the best travel hacks, it's the professionals that fly for a living.
Read more »
JPMorgan upgrades this regional bank stock with limited exposure to commercial real estate, sees 25% gainJPMorgan thinks there's a buying opportunity in regional bank Valley National.
Read more »
Leasing a new headquarters could cost NJ Transit almost $400M over 25 yearsA proposed 25-year lease of space at 2 Gateway Center in Newark for NJ Transit's headquarters could cost up to $400 million over the lease period.
Read more »